Arthur Ryan, a Director at Regeneron Pharmaceuticals Inc (REGN), recently sold 100 shares of the company. This transaction reduced his total holdings to 17,803 shares. According to GuruFocus data, Regeneron has recorded five insider selling transactions with no insider purchases over the past year. Despite the insider sale, GuruFocus currently classifies REGN as "modestly undervalued" with a GF Value of $932.22, while the stock trades at $778.53. Analysts suggest this small sale is unlikely to significantly impact market sentiment given the company's size and the director's remaining substantial stake.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis